Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Oncovin TM

Active ingredients: vincristine

What it is used for

Oncovin is indicated in acute leukaemia. It has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas(lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, Wilms' tumour, osteogenic sarcoma, mycosis fungoides, Ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecologic tumours of childhood. Patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment may respond to Oncovin. Current practices of cancer chemotherapy involve the simultaneous use of several agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. It is rarely possible to achieve equally good results with single-agent treatment. Thus Oncovin is often chosen as part of polychemotherapy because of lack of significant bone-marrow suppression( at recommended doses) and because of its unique clinical toxicity(neuropathy). See DOSAGE AND ADMINISTRATION for possible increased toxicity when used in combination therapy. In recent years, multiple-agent regimens have been developed for the treatment of a variety of malignant disorders in children. Paediatric patients with neuroblastoma, osteogenic sarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilms' tumour, Hodgkin's disease, non-Hodgkin's lymphomas, embryonal carcinoma of the ovaries, and rhabdomyosarcoma of the uterus should be considered candidates for such polychemotherapy treatment. Close cooperation among oncologists, paediatricians, radiologists, and surgeons is required in order to achieve the best possible results. Patients with true idiopathic thrombocytopenic purpura refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to Oncovin, but the drug is not recommended as primary treatment for this order. Recommended weekly doses of Oncovin given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any results with additional doses.

How to take it

This medicine is a pack that contains more than one part.

Part 1: Injection, powder for

A white lyophilised powder

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

Part 2: Diluent, not applicable

A clear colourless solution

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Storage instructions

  • Store at 2 to 8 degrees Celsius
  • Shelf lifetime is 3 Years.

Do I need a prescription?

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

  • 1 vial of powder - 1mg pack

We are unable to tell you if you need a prescription for these medicines. You can ask your pharmacist. This medicine is Not Scheduled.

  • vial of diluent - 10mL pack

Pregnant or planning a pregnancy?

For the active ingredient vincristine

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Back to top back to top

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo